OCEA_OUT_1 [2025-03-26 05:45:09 -0400] 2549 Bytes | 673 tokens | Cum: 673 tkns (8.41% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Ocean Biomedical (OCEA) hit my radar screen, up to 0.091 from a prev close of 0.0568 Do you think its got more juice or is it lacking potential? It's 5:45:07 AM on Wed Mar 26, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Ocean Biomedical:

C1 - Feb-10-25 08:00AM - Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
C2 - Jan-29-25 08:30AM - Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
C3 - Nov-22-24 04:45PM - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
C4 - Oct-22-24 04:45PM - Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
C5 - Oct-15-24 07:30AM - Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
C6 - Oct-01-24 08:01AM - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
C7 - Aug-27-24 08:01AM - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms
C8 - Aug-23-24 04:30PM - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Ocean Biomedical (OCEA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

OCEA_OUT_3 [2025-03-26 05:45:10 -0400] 1039 Bytes | 292 tokens | Cum: 967 tkns (12.09% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development**
Date: Feb-10-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/10/3023373/0/en/Ocean-Biomedical-Announces-Breakthrough-Findings-in-EGFR-Mutant-Lung-Cancer-and-Plans-for-FDA-Alignment-on-Next-Stage-Development.html

February 10, 2025 08:00 ET| Source:Ocean Biomedical, Inc.Ocean Biomedical, Inc.

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest

Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --Ocean Biomedical (NASDAQ: OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung ca

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_5 [2025-03-26 05:45:12 -0400] 579 Bytes | 165 tokens | Cum: 1134 tkns (14.17% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-13T13:33:32Z - Ocean Biomedical stock plunges to 52-week low of $0.07 By Investing.com...
A2 - 2025-02-27T23:44:02Z - BB's Stock Haven : $OCEA DD 101 -- Malaria Patent: "This p......

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OCEA_OUT_7 [2025-03-26 05:45:13 -0400] 1038 Bytes | 280 tokens | Cum: 1416 tkns (17.70% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Ocean Biomedical stock plunges to 52-week low of $0.07 By Investing.com**Date: 2025-03-13Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/company-news/ocean-biomedical-stock-plunges-to-52week-low-of-007-93CH-3927177Ocean Biomedical Inc. (OCEA) shares have tumbled to a 52-week low, reaching a price level of just $0.07. With a market capitalization of $2.7 million, the company's stock is showing signs of being oversold according to InvestingPro technical indicators. This significant drop reflects a stark downturn for the company, which has seen its stock value erode by an alarming 98% over the past year, with particularly steep declines of 92% in the past six months. The company's financial health score of 1.72 is rated as 'WEAK' by InvestingPro, which offers 10+ additional indicators to help investors navigate this cha

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_9 [2025-03-26 05:45:14 -0400] 1398 Bytes | 397 tokens | Cum: 1815 tkns (22.69% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-22T21:45:00Z - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
B2 - 2024-10-22T20:45:00Z - Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
B3 - 2024-10-01T12:01:00Z - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
B4 - 2024-06-05T11:01:00Z - Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
B5 - 2024-05-30T11:44:00Z - Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
B6 - 2024-05-16T12:01:00Z - Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OCEA_OUT_11 [2025-03-26 05:45:16 -0400] 1038 Bytes | 273 tokens | Cum: 2090 tkns (26.12% of 8k)
==========================================================================

Showing B3 (chunk 1 of 2): B3:
**Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/10/01/2956091/0/en/Ocean-Biomedical-Inc-NASDAQ-OCEA-Announces-Publication-of-New-Data-Deepening-Understanding-of-Novel-Cancer-Immunotherapy-Treatment-Approach-Targeting-CHI3L1-and-its-Ability-to-Inhi.htmlOcean Biomedical has published new research that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases. The research demonstrates the complex ways that CHI3L1 inhibits macrophage phagocytosis, providing a mechanistic explanation for the ability of CHI3L1 to stimulate immune checkpoint inhibi

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_13 [2025-03-26 05:45:19 -0400] 212 Bytes | 58 tokens | Cum: 2150 tkns (26.88% of 8k)
==========================================================================

Showing B3 (chunk 2 of 2): tors and inhibit essential adaptive immune responses in cancer and COPD.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_15 [2025-03-26 05:45:21 -0400] 1058 Bytes | 331 tokens | Cum: 2505 tkns (31.31% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-01-13 10-Q PART I-FIN INFO

Item 1. Fin Stmnts

OCEAN BIOMEDICAL, INC.

Condensed Cons Balance Sheets

(in thousands, except share and per share data)

(unaudited)

September 30,

December 31,

ASSETS CURRENT ASSETS: Cash $ - $ 4 Restricted cash 24...

S2 - 2024-12-23 10-Q PART I-FIN INFO

Item 1. Fin Stmnts

OCEAN BIOMEDICAL, INC.

Condensed Cons Balance Sheets

(in thousands, except share and per share data)

(unaudited)

June 30,

December 31,

ASSETS CURRENT ASSETS: Cash $ 4 $ 4 Restricted cash 225 1,0...

S3 - 2024-12-23 10-Q PART I-FIN INFO

Item 1. Fin Stmnts

OCEAN BIOMEDICAL, INC.

Condensed Cons Balance Sheets

(in thousands, except share and per share data)

(unaudited)

March 31,

December 31,

ASSETS CURRENT ASSETS: Cash $ 19 $ 4 Restricted cash 500 1...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OCEA_OUT_17 [2025-03-26 05:45:22 -0400] 1038 Bytes | 318 tokens | Cum: 2825 tkns (35.31% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
PART I-FINANCIAL INFORMATION

Item 1. Financial Statements

OCEAN BIOMEDICAL, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(unaudited)

June 30,

December 31,

ASSETS CURRENT ASSETS: Cash $ 4 $ 4 Restricted cash 225 1,000 Prepaid expenses 1,048 1,105 Total current assets 1,277 2,109 Investment in Virion 574 3,392 TOTAL ASSETS $ 1,851 $ 5,501 LIABILITIES AND STOCKHOLDERS DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses $ 17,180 $ 16,185 Accrued expenses related party 916 946 Short-term loans, net of issuance costs 10,980 12,118 SPA Warrant 1,662 764 Total current liabilities 30,738 30,013 NONCURRENT LIABILITIES Fixed maturity consideration 4,790 4,123 Backstop put option liability 55,881 58,523 Virion contribution liability 3,185 3,605 Total liabilities 94,594 96,264 STOCKHOLDERS DEFICIT: Common stock, $ 0.0

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_19 [2025-03-26 05:45:32 -0400] 1038 Bytes | 328 tokens | Cum: 3155 tkns (39.44% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): 001 par value; 300,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively, 34,868,628 and 34,649,046 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. - - Additional paid-in capital 107,547 105,292 Accumulated deficit ( 200,290 ) ( 196,055 ) Total stockholders deficit ( 92,743 ) ( 90,763 ) TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT $ 1,851 $ 5,501

See accompanying notes to the unaudited condensed consolidated financial statements

OCEAN BIOMEDICAL, INC.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

2024 2023 2024 2023 Three Months Ended

June 30,

Six Months Ended

June 30,

2024 2023 2024 2023 OPERATING EXPENSES: Research and development $ - $ 28 $ 26 $ 421 General and administrative 682 2,804 1,251 7,798 Total operating expenses 682 2,832 1,277 8,219 OPE

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

OCEA_OUT_21 [2025-03-26 05:45:46 -0400] 4243 Bytes | 1185 tokens | Cum: 4536 tkns (56.70% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| Volume: 7,259,260 | SMA50: -71.62% | Market Cap: 7.99M | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| Avg Volume: 36.02M | SMA200: -92.71% | Shs Outstand: 140.59M | Short Float: 4.86% | Employees: 7 | EPS Surprise: -151.28% |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| Rel Volume: 0.20 | Perf Week: -3.40% | Shs Float: 117.78M | Short Ratio: 0.16 | Debt/Eq: - | P/E: - |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| RSI (14): 24.88 | Perf Month: -52.67% | Inst Own: 2.62% | Short Interest: 5.72M | Sales Y/Y TTM: - | Earnings: - |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| ATR (14): 0.02 | Perf Quarter: -90.36% | Insider Own: 16.22% | Beta: 1.52 | ROE: -1691.47% | |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+
| SMA20: -26.48% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: - | |
+--------------------+-----------------------+-----------------------+-------------------------+----------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': -2113000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -26619000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.0568
Average Volume: 15959078.64
30-Day High: 0.12
30-Day Low: 0.0568

[Detailed Financials: Q3 2024]
- Total Assets: $1,132,000.0
- Total Liabilities: $99,217,000.0
- Total Equity: $-98,085,000.0
- Current Assets: $1,042,000.0
- Current Liabilities: $33,649,000.0

[Income Statement: Q3 2024]
- Revenue: $-461,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $775,000

[Detailed Financials: Q2 2024]
- Total Assets: $1,851,000.0
- Total Liabilities: $94,594,000.0
- Total Equity: $-92,743,000.0
- Current Assets: $1,277,000.0
- Current Liabilities: $30,738,000.0

[Income Statement: Q2 2024]
- Revenue: $-515,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.63

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-290,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

OCEA_OUT_23 [2025-03-26 05:45:48 -0400] 676 Bytes | 167 tokens | Cum: 4964 tkns (62.05% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

OCEA_IN_25 [2025-03-26 05:45:48 -0400] 126 Bytes | 29 tokens | Cum: 5021 tkns (62.76% of 8k)
==========================================================================

====================================
[2025-03-26 02:45:48] # Analysis Completed
Elapsed Time: 40.68 seconds